Parexel said it has acquired Vitrana, an AI pharmacovigilance technology developer, as part of an effort to reduce the operational burden of drug safety reporting for clinical studies. The acquisition targets high-volume adverse event processing—automating tasks such as case intake, data extraction, entity mapping, narrative generation, and reconciliation. In an interview, Parexel president of patient safety services and clinical logistics Sanjay Vyas said regulators are increasing both the volume and complexity of safety reporting requirements, making manual workflows a growing bottleneck. He added that the Vitrana platform is intended to help safety teams focus on product and patient safety. Parexel said the technology is currently deployed across more than 30 customers, with internal metrics indicating a 60% reduction in case processing time and a 75% reduction in manual reconciliation tasks. Financial terms were not disclosed.